Investigator

Charis Eng

ACS/Hardis Professor and Chair · Cleveland Clinic, Genomic Medicine Institute

About

Research Interests

CECharis Eng
Papers(3)
Physical Activity Dur…Weight Gain and the R…Bilateral Oophorectom…
Collaborators(10)
Olufunmilayo I. Olopa…William D. FoulkesSteven NarodFergus J. CouchTomasz HuzarskiBeth Y. KarlanLeigha SenterLouise BordeleauNadine TungChristian F. Singer
Institutions(11)
Cleveland ClinicThe University of Chi…McGill UniversityWomens College Hospit…Mayo ClinicPomeranian Medical Un…University of Califor…The Ohio State Univer…Juravinski Cancer Cen…Beth Israel Deaconess…Medical University Of…

Papers

Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation

Abstract In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk. Whether this is true among women at high risk due to a pathogenic variant (mutation) in the BRCA1 or BRCA2 genes has not been evaluated. Thus, we performed a matched case–control study to evaluate the association between adolescent and early-adulthood physical activity and ovarian cancer. BRCA mutation carriers who completed a research questionnaire on various exposures and incident disease and with data available on physical activity were eligible for inclusion. Self-reported activity at ages 12–13, 14–17, 18–22, 23–29, and 30–34 was used to calculate the average metabolic equivalent of task (MET)-hours/week for moderate, vigorous, and total physical activity during adolescence (ages 12–17) and early-adulthood (ages 18–34). Conditional logistic regression was used to estimate the OR and 95% confidence intervals (CI) of invasive ovarian cancer associated with physical activity. This study included 215 matched pairs (mean age = 57.3). There was no association between total physical activity during adolescence (ORhigh vs. low = 0.91; 95% CI: 0.61–1.36; Ptrend = 0.85), early-adulthood (ORhigh vs. low = 0.78; 95% CI: 0.51–1.20; Ptrend = 0.38) and overall (ORhigh vs. low = 0.81; 95% CI: 0.54–1.23; Ptrend = 0.56) and ovarian cancer. Findings were similar for moderate (Ptrend ≥ 0.25) and vigorous (Ptrend ≥ 0.57) activity. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, physical activity should continue to be encouraged to promote overall health. Significance: In this matched case–control study, we observed no association between physical activity during adolescence or early-adulthood and subsequent risk of ovarian cancer. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, being active remains important to promote overall health and well-being.

Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers

Abstract Background: Weight gain and other anthropometric measures on the risk of ovarian cancer for women with BRCA mutations are not known. We conducted a prospective analysis of weight change since age 18, height, body mass index (BMI) at age 18, and current BMI and the risk of developing ovarian cancer among BRCA1 and BRCA2 mutation carriers. Methods: In this prospective cohort study, height, weight, and weight at age 18 were collected at study enrollment. Weight was updated biennially. Cox proportional hazards models were used to estimate the hazard ratio (HR) and 95% confidence intervals (CI) for ovarian cancer. Results: This study followed 4,340 women prospectively. There were 121 incident cases of ovarian cancer. Weight gain of more than 20 kg since age 18 was associated with a 2-fold increased risk of ovarian cancer, compared with women who maintained a stable weight (HR, 2.00; 95% CI, 1.13–3.54; P = 0.02). Current BMI of 26.5 kg/m2 or greater was associated with an increased risk of ovarian cancer in BRCA1 mutation carriers, compared with those with a BMI less than 20.8 kg/m2 (Q4 vs. Q1 HR, 2.13; 95% CI, 1.04–4.36; P = 0.04). There were no significant associations between height or BMI at age 18 and risk of ovarian cancer. Conclusions: Adult weight gain is a risk factor for ovarian cancer in women with a BRCA1 or BRCA2 mutation. Impact: These findings emphasize the importance of maintaining a healthy body weight throughout adulthood in women at high risk for ovarian cancer.

Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal

Abstract Background: The lack of consensus on whether bilateral oophorectomy impacts risk of developing breast cancer among BRCA1 mutation carriers might be attributed to various biases, specifically, cancer-induced testing bias due to inclusion of prevalent cases. We conducted two complementary matched case–control analyses to evaluate the association of oophorectomy and BRCA1 breast cancer. Methods: A research questionnaire was administered every two years to collect information on exposures and disease. In the first analysis, we limited the study to prevalent breast cancer cases (diagnosed prior to study entry; n = 2,962) who were matched to controls on year of birth and country of residence (n = 4,358). In the second approach, we limited to 330 incident cases (diagnosed in the follow-up period) and 1,548 matched controls. Conditional logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence intervals (CI) of invasive breast cancer. Results: In the first approach, there was a significant inverse association between oophorectomy and the risk of developing breast cancer [OR = 0.43; 95% confidence interval (CI), 0.34–0.55; P < 00001]. In the second approach, there was no association between oophorectomy and risk (OR = 1.21; 95% CI, 0.87–1.70; P = 0.26). Conclusions: The inclusion of women with a personal history of breast cancer prior to ascertainment likely impacts upon the association of oophorectomy and BRCA1 breast cancer risk. Impact: Oophorectomy is unlikely a determinant of breast cancer risk in BRCA1 mutation carriers but should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.

611Works
3Papers
22Collaborators
Autism Spectrum DisorderNeoplasmsThyroid NeoplasmsBreast NeoplasmsDisease Models, AnimalOvarian Neoplasms

Positions

2005–

ACS/Hardis Professor and Chair

Cleveland Clinic · Genomic Medicine Institute

2005–

Director

Cleveland Clinic · Center for Personalized Genetic Healthcare

2005–

Professor and Vice Chair

Case Western Reserve University School of Medicine · Genetics and Genome Sciences

2002–

Klotz Professor and Director

Ohio State University · Medicine, Division of Human Genetics

1999–

Director, Clinical Cancer Genetics Program

Ohio State University · James Cancer Hospital and Comprehensive Cancer Center

1999–

Associate Professor

Ohio State University · Medicine, Division of Human Genetics

1995–

AAssistant Professor of Medicine and Active Staff Physician

Dana Farber Cancer Institute · Medical Oncology and Cancer Epidemiology and Control, Charles A Dana Human Cancer Genetics Program

1995–

Assistant Professor

Harvard Medical School · Medicine

1993–

Hon. Senior Registrar

Royal Marsden Hospital · Clinical Genetics

1992–

Hon. Senior Registrar, Clinical Cancer Genetics

Addenbrooke's Hospital · Medical Genetics

Education

1995

CRC Dana-Farber Fellow in Human Cancer Genetics

University of Cambridge · Pathology, Division of Genetic Pathology

1995

Clinical Fellow

Dana Farber Cancer Institute · Medical Oncology

1991

Resident

Beth Israel Deaconess Medical Center · Medicine

1988

MD

University of Chicago · Pritzker School of Medicine

1986

PhD

University of Chicago · Developmental Biology, Biological Sciences Division of Pritzker School of Medicine

1982

BA Honors

University of Chicago College · Biological Sciences Collegiate Division

Country

US

Keywords
Endocrine CancerMicrobiomeCancer Family HistoryCancer ResearchSDHCMetabolomeSDHDCancer PredispositionHeritable Cancer SyndromesBreast CancerCancer MetagenomicsSDHASDHBCowden syndromePTENAutism ResearchPheochromocytomaKILLINKLLNIntegrative GenomicsThyroid CancerCancer Susceptibility